ABUS250117C7000
- 0.10
- 0.000.00%
Arbutus Biopharma Newsroom
Antisense & RNAi Therapeutics Market Report 2024, Featuring Profiles of Alnylam Pharmaceuticals, Arbutus Biopharma, Benitec Biopharma, GSK, Ionis Pharmaceuticals, Sanofi, Sarepta Therapeutics & More - ResearchAndMarkets.com
Here's Why Arbutus (ABUS) Surged in Q3
Whitefort Capital Sends Letter To Arbutus Biopharma Board Of Directors; Believes Now Is The Time For Arbutus To Pursue A License And Collaboration Agreement With A Strategic Partner And Explore All Options For HBV Portfolio
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $5
Arbutus Biopharma Analyst Ratings
Barinthus Biotherapeutics Shares Are Trading Lower. The Company Announced Data From the Ongoing Phase 2b HBV003 Clinical Trial.
Arbutus Biopharma's Promising CHBV Treatment Results
Arbutus Biopharma's Trial Boosts Hepatitis B Treatment
Express News | Arbutus and Barinthus Bio Announce New Data From the IM-Prove II Trial Showing That the Addition of Nivolumab Increased Rates of Hbsag Loss in People With Chronic Hepatitis B
Arbutus to Present at Jefferies London Healthcare Conference
Arbutus Biopharma's Promise and Risks: A Hold Rating Amid Early Trial Success and Legal Uncertainty
H.C. Wainwright Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5
Q3 2024 Arbutus Biopharma Corp Earnings Call
Arbutus Biopharma Is Maintained at Buy by Chardan Capital
Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $4.5
Express News | Arbutus Biopharma Corp Files for Mixed Shelf of up to $300 Mln - SEC Filing
Arbutus Biopharma | 10-Q: Q3 2024 Earnings Report
Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript